These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33934465)

  • 1. An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report.
    Hendin HM; Penn AD
    Bipolar Disord; 2021 Nov; 23(7):733-735. PubMed ID: 33934465
    [No Abstract]   [Full Text] [Related]  

  • 2. "A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.
    DellaCrosse M; Pleet M; Morton E; Ashtari A; Sakai K; Woolley J; Michalak E
    PLoS One; 2022; 17(12):e0279073. PubMed ID: 36516137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.
    Morton E; Sakai K; Ashtari A; Pleet M; Michalak EE; Woolley J
    J Psychopharmacol; 2023 Jan; 37(1):49-60. PubMed ID: 36515370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms.
    Lugo-Radillo A; Cortes-Lopez JL
    J Psychoactive Drugs; 2021; 53(2):146-148. PubMed ID: 33225874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unpredictable Behavior Under the Influence of "Magic Mushrooms": A Case Report and Review of the Literature.
    Honyiglo E; Franchi A; Cartiser N; Bottinelli C; Advenier AS; Bévalot F; Fanton L
    J Forensic Sci; 2019 Jul; 64(4):1266-1270. PubMed ID: 30548541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Mushrooms to Myolysis: A Case of Rhabdo in Psilocybin-Induced Mood and Psychotic Disorder.
    Suleiman M; Basu A; Belal S; Jacob T
    J Nerv Ment Dis; 2022 Aug; 210(8):638-639. PubMed ID: 35900779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Automutilation after consumption of hallucinogenic mushrooms].
    Attema-de Jonge ME; Portier CB; Franssen EJ
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2869-72. PubMed ID: 18257429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
    Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1268-1278. PubMed ID: 27578767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hallucinogenic mushrooms].
    Reingardiene D; Vilcinskaite J; Lazauskas R
    Medicina (Kaunas); 2005; 41(12):1067-70. PubMed ID: 16401965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacology of psilocybin.
    Passie T; Seifert J; Schneider U; Emrich HM
    Addict Biol; 2002 Oct; 7(4):357-64. PubMed ID: 14578010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
    Jastrzebski M; Bala A
    Psychiatr Pol; 2013; 47(6):1157-67. PubMed ID: 25007546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Psychoactive mushrooms - an update].
    Supprian T; Frey U; Supprian R; Rösler M; Wanke K
    Fortschr Neurol Psychiatr; 2001 Dec; 69(12):597-602. PubMed ID: 11753749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weaning and Mixed Mania-A Case Report.
    Sharma V
    J Hum Lact; 2018 Nov; 34(4):745-748. PubMed ID: 29928823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students.
    Hallock RM; Dean A; Knecht ZA; Spencer J; Taverna EC
    Drug Alcohol Depend; 2013 Jun; 130(1-3):245-8. PubMed ID: 23265089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
    Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1279-1295. PubMed ID: 27856683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DARK Classics in Chemical Neuroscience: Psilocybin.
    Geiger HA; Wurst MG; Daniels RN
    ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-reported negative outcomes of psilocybin users: A quantitative textual analysis.
    Bienemann B; Ruschel NS; Campos ML; Negreiros MA; Mograbi DC
    PLoS One; 2020; 15(2):e0229067. PubMed ID: 32084160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent psychiatric symptoms after eating psilocybin mushrooms.
    Benjamin C
    Br Med J; 1979 May; 1(6174):1319-20. PubMed ID: 571748
    [No Abstract]   [Full Text] [Related]  

  • 20. Antidepressant-associated mania or hypomania: a comparison with personality and bipolarity features of bipolar I disorder.
    Saatcioglu O; Erim R; Tomruk N; Oral T; Alpay N
    J Affect Disord; 2011 Nov; 134(1-3):85-90. PubMed ID: 21632117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.